Homepage / CARE & HOPE


Our vision goes beyond technological advancement. We aim to bring care and hope closer to all.



With our gMendel®Care initiative, we aim to bring accurate diagnosis and fair, equal care opportunities closer to all families facing genetic disorders. The gMendel®Care initiative includes the Basic Carrier Test (BCT) for future parents (before conception), the Non-Invasive Prenatal Test (NIPT) (during pregnancy) and the Newborn Screening Test (NBS) (after birth).

Newborn screening can be done much more efficiently with the gMendel®Test. Thanks to the gMendel® technology, screening can be democratized at the accuracy of a diagnosis, with sensitivity and specificity rate of over 99%. The gMendel® technology allows scientists to sequence any DNA fragment length, from short to ultra long, and therefore characterize more genetic variation, detect tandem repeats and genetic mosaicism, and eventually unlimited number of genetic disorders.

The use of artificial intelligence enables complete automation of the screening, meaning that hundreds of samples can run in one flow cell, as directed by the innovative library preparation protocol. 


The library needs minimal training and runs on a cloud-based platform. Therefore, the AI-powered predictive outcome can be released in less than 24 hours.

The gMendel®Test is a certified and scalable in vitro diagnostic test that, in contrary to common, non-scalable Laboratory Developed Tests (LDT), can be used at all times, regardless of the changes in local or broader regulatory frameworks.

Our vision is to fulfil as many newborn screening panel requirements in as many countries as possible and include the gMendel®Test in national healthcare protocols. To this end, we are working with all possible stakeholders to promote systematic data collection and knowledge sharing of genetic disorders and contribute to the development of integrated healthcare services, regardless of social or financial inequalities of the patients.



Our end-to-end approach, the simplicity, upgradability and extensibility, namely the ability to add new genetic disorders, operability, scalability, and the superior user experience are all represented in the gMendel®Test, our efficient and affordable diagnostic tool with greater detection capabilities, applicable to genetic disorders beyond the available technologies.

Our gMendel®Hope initiative includes:

  • Epigenetics. There is emerging evidence that epigenetics play an important role in health and disease. Epigenetic modifications may exert their effect independently or complementary to genetic variants and have the potential to modify gene expression. These modifications are dynamic, potentially heritable, and can be induced by environmental stimuli or chemical substances or medicines.


  • Neurological genetic disorders
  • Graft vs. Host disease

Our ultimate goal is to be able to diagnose all known genetic disorders, nearly 8000, through Whole Genome via Targeted Sequencing.